stability indicating assay method for simultaneous estimation of nebivolol and valsartan in pharmaceutical dosage form by rp-hplc

A simple, rapid, precise, and accurate isocratic reversed-phase stability indicating hplc method was developed and validated for simultaneous determination of the nebivolol and valsartan in the tablet dosage form. the effective chromatographic separation was achieved by a ymc pack pro octadecyl silane (150×4.6 mm, 3 μm) column using a mobile phase composed of methanol: acetonitrile: 0.05 m potassium dihydrogen phosphate buffer (ph=3.0 with 10% ortho phosphoric acid after addition of 0.2% triethylamine) (30:30:40, v/v/v) at a flow rate of 1 ml/min and uv detection at 282 nm. drugs were subjected to the acid, base, oxidation, heat, and photolysis to apply the stress. linearity ranges were 5–30 μg/ml (r2= 0.9989) for nebivolol and 80-480 μg/ml (r2=0.9991) for valsartan. limit of detection was 0.38 μg/ml and 1.08 μg/ml for nebivolol and valsartan, respectively. the limit of quantification for the nebivolol and valsartan was 1.15 μg/ml and 3.27 μg/ml, respectively.